Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Liver Neoplasms 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Lung Neoplasms 1Liver Cirrhosis 1Hypoxia 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 4pimonidazole 2TH 302 2gadobutrol 1fluoromisonidazole 1Surgical Procedures, Operative 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Radiotherapy 1Propofol 1Positron Emission Tomography Computed Tomography 1Pancreaticoduodenectomy 1Oxygen 1NVP-BKM120 1Ketamine 1Gemcitabine 1Ferrosoferric Oxide 1Dexmedetomidine 1Blood Specimen Collection 1Biopsy 1Bacterial Load 1Atovaquone 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hypoxia × fluoromisonidazole × Clear all
NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡